Adult Burkitt lymphoma: Advances in diagnosis and treatment

ONCOLOGY

Volumn 22, Issue 13, 2008, Pages 1508-1517

  Aldoss, Ibrahim T ^a   Weisenburger, Dennis D ^b   Fu, Kai ^b   Chan, Wing C ^b   Vose, Julie M ^c   Bierman, Philip J ^c   Bociek, R Gregory ^c   Armitage, James O ^c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; SEROTONIN UPTAKE INHIBITOR; TENIPOSIDE; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME DELETION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; ONCOGENE; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GENES, MYC; HUMANS; IFOSFAMIDE; LEUCOVORIN; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; PREDNISONE; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 58049094393     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Magrath IT, Janus C, Edwards BK, et al: An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63:1102-1111, 1984.
2. Kantarjian HM, Walters RS, Keating MJ, et al: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocytic leukemia. J Clin Oncol 8:994-1004, 1990.
3. Bernasconi C, Brusamolino E, Pagnucco G, et al: Burkitt's lymphoma/ leukemia: A clinicopathologic study on 24 adult patients. Leukemia 5:90-94, 1991.
4. Ostronoff M, Soussain C, Zambon E, et al: Burkitt's lymphoma in adults: A retrospective study of 46 cases. Nouv Rev Fr Hematol 34:389-397, 1992.
5. Burkitt DP: Sarcoma involving jaws in African children. Br J Surg 46:218-223, 1958.
6. Burkitt D, O'Conor GT: Malignant lymphoma in African children: I. Clinical syndrome. Cancer 14:258-269, 1961.
7. Murphy SB, Fairclough DL, Hutchison RE, et al: Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J ClinOncol 7:186-193, 1989.
8. Diebold J, Jaffe E, Raphael M, et al: Burkitt lymphoma, in Jaffe E, Harris N, Stein H, et al (eds): Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues, 181-184. Lyon, France; IARC Press; 2001.
9. Cardy A, Sharp L, Little J: Burkitt's lymphoma: A review of the epidemiology. Kuwait Med J 33:293-306, 2001.
10. Makata AM, Toriyama K, Kamidigo NO, et al: The pattern of pediatric solid malignant tumors in Western Kenya, East Africa, 1979-1994: An analysis based onhistopathologic study. Am J Trop Med Hyg 54:343-347, 1996.
11. Cairo MS, Sposto R, Perkins SL, et al: Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience. Br J Haematol 120:660-670, 2003.
12. Agrath I: The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55:133-270, 1990.
13. Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020, 2004.
14. Boerma EG, van Imhoff GW, Appel IM, et al: Gender and age-related differences in Burkitt lymphoma - epidemiological and clinical data from The Netherlands. Eur J Cancer 40:2781-2787, 2004.
15. Sariban E, Donahue A, Magrath IT: Jaw involvement in American Burkitt's lymphoma. Cancer 53:141-146, 1984.
16. Magrath IT, Sariban E: Clinical features of Burkitt's lymphoma in the USA. IARC Sci Puble 60:119-127, 1985..
17. Hugh JC, Jackson FI, Hanson J, et al: Primary breast lymphoma. An immunohistologic study of 20 new cases. Cancer 66:2602-2611, 1990.
18. Burmeister T, Schwartz S, Horst HA, et al: Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: Correlation with morphology, immunology and clinical features. Leukemia 19:1391-1398, 2005.
19. Gong JZ, Stenzel TT, Bennett ER, et al: Burkitt lymphoma arising in organ transplant recipients: A clinicopathologic study of five cases. Am J Surg Pathol 27:818-827, 2003.
20. Xicoy B, Ribera JM, Esteve J, et al: Post-transplant Burkitt's leukemia or lymphoma. Study of five cases treated with specific intensive therapy (PETHEMA ALL-3/97 trial). Leuk Lymphoma 44:1541-1543, 2003.
21. Ferry JA: Burkitt's lymphoma: Clinicopathologic features and differential diagnosis. Oncologist 11:375-383, 2006.
22. Knowles DM: Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 17:785-820, 2003.
23. Gabarre J, Raphael M, Lepage E, et al: Human immunodeficiency virus-related lymphoma: Relation between clinical features and histoloical subtypes. Am J Med 11:704-711, 2001.
24. Lim ST, Karim R, Nathwani BN, et al: AIDS-Related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. J Clin Oncol 23:4430-4438, 2005.
25. Sandler AS, Kaplan LD: Diagnosis and management of systemic non-Hodgkin's lymphoma in HIV. Hematol Oncol Clin North Am 10:1111-1124, 1996.
26. Ostronoff M, Soussain C, Zambon E, et al: Burkitt's lymphoma in adults: A retrospective studay of 46 cases. Nouv Rev Fr Hematol 34:389-397, 1992.
27. Harris N, Jaffe E, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
28. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
29. Braziel RM, Arber DA, Slovak ML, et al: The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 97:3713-3720, 2001.
30. Küppers R, Klein U, Hansmann M, et al: Cellular origin of human B-cell lymphomas. N Engl J Med 341:1520-1529, 1999.
31. Jain R, Roncella S, Hashimoto S, et al: A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma. J Immunol 153:45-52, 1994.
32. Chapman CJ, Zhou JX, Gregory C, et al: VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood 88:3562-3568, 1996.
33. Chapman CJ, Wright D, Stevenson FK: Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis. Leuk Lymphoma 30:257-267, 1998.
34. McClure RF, Remstein ED, Macon WR, et al: Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29:1652-1660, 2005.
35. Dogan A, Bagdi E, Munson P, et al: CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846-852, 2000.
36. Van der Burg M, Barendregt BH, van Wering ER, et al: The presence of somatic mutations in immunoglobulin genes of B cell acute lymphoblastic leukemia (ALL L3) supports assignment as Burkitt's leukemia-lymphoma rather than B-lineage ALL. Leukemia 15:1141-1143, 2001.
37. Macpherson N, Lesack D, Klasa R, et al: Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: Cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17:1558-1567, 1999.
38. Nakamura N, Nakamine H, Tamaru J, et al: The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol 15:771-776, 2002.
39. Haralambieva E, Boerma EJ, van Imhoff GW, et al: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 29:1086-1094, 2005.
40. Magrath IT, Freeman CB, Bizzo P, et al: Characterization of lymphoma-derived cell lines: Comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers. J Natl Cancer Inst 64:64:477-483, 1980.
41. Hecht J, Aster J: Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3703-3721, 2000.
42. Pelicci PG, Knowles DMd, Magrath I, et al: Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U SA 83:2984-2988, 1986.
43. Shiramizu B, Barriga F, Neequaye J, et al: Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: Relevance to geography and Epstein-Barr virus association. Blood 77:1516-1526, 1991.
44. Bhatia K, Spangler G, Gaidano G, et al: Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood 84:883-888, 1994.
45. Joos S, Falk MH, Lichter P, et al: Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet 1:625-632, 1992.
46. Frost M, Newell J, Lones MA, et al: Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 121:384-392, 2004.
47. Dave SS, Fu K, Wright GW, et al: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442, 2006.
48. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006.
49. Thangavelu M, Olopade O, Beckman E, et al: Clinical, morphologic, cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14) (q24;q32) or t(8;22) (q24;q11). Genes Chromosomes Cancer 2:147-158, 1990.
50. Le Gouill S, Talmant P, Touzeau C, et al: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/ c-MYC rearrangement. Haematologica 92:1335-1342, 2007.
51. Nunez G, London L, Hockenberry D, et al: Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602-3610, 1990.
52. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990.
53. Karsan A, Gascoyne RD, Coupland RW, et al: Combination of t(14;18) and Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma 10:433-444, 1991.
54. Liu D, Shimonov J, Primanneni S, et al: t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia. Mol Cancer 6:35, 2007.
55. Van Ooteghem RB, Smit EM, Beishuizen A, et al: A new B-cell line showing a complex translocation (8;14;18) and BCL2 rearrangement. Cancer Genet Cytogenet 74:87-94, 1994.
56. Zimonjic DB, Keck-Waggoner C, Popescu NC: Novel genomic imbalances and chromosome translocations involving c-myc gene in Burkitt's lymphoma. Leukemia 15:1582-1588, 2001.
57. Preudhomme C, Dervite I, Wattel E: Clinical significance of p53 mutation in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases. J Clin Oncol 13:812-820, 1995.
58. Gaidano, G, Ballerini, P, Gong, JZ, et al: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 88:5413-5417, 1991.
59. Gaidano G, Hauptschein RS, Parsa NZ, et al: Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80:1781-1787, 1992.
60. Bernstein JI, Coleman CN, Strickler JG, et al: Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 4:847-858, 1986.
61. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
62. Hoelzer D, Ludwig WD, Thiel E, et al: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87:495-508, 1996.
63. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664-674, 1995.
64. Divine M, Cassasus P, Koscielny S, et al: Adult Burkitt lymphoma. A prospective multicenter trial with the LMB protocol (abstract 80). Proc Am Soc Clin Oncol 19, 2000.
65. Divine M, Casassus P, Koscielny S, et al: Burkitt lymphoma in adults: A prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 16:1928-1935, 2005.
66. Adde M, Shad A, Venzon D, et al: Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 25:33-39, 1998.
67. Mead GM, Sydes MR, Walewski J, et al: An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274, 2002.
68. LaCasce A, Howard O, Li S, et al: Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leuk Lymphoma 45:761-767, 2004.
69. Thomas D, Cortes J, O'Brien S, et al:. Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470, 1999.
70. Thomas DA, Faderl S, O'Brien S, et al: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006.
71. NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphoma, V.3.2008. Available at www.nccn.org. Accessed October 29, 2008.
72. Nademanee A, Molina A, O'Donnell MR, et al: Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate - and high-grade lymphoma: International index high and high-intermediate risk group. Blood 90:3844-3852, 1997.
73. Song, KW, Barnett, MJ, Gascoyne, RD, et al: Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133:634-637, 2006.
74. Sweetenham J, Pearce R, Taghipour G, and et al: Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in the first remission or at relapse: Results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465-2472, 1996.
75. Grigg AP, Seymour JF: Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma 43:889-892, 2002.
76. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003.
77. Ungkanont A, Mongkonsritrakoon W, Jootarl S, et al: Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. Bone Marrow Transplant 26:1351-1354, 2000.
78. Serafeim A, Holder MJ, Grafton G, et al: Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212-3219, 2003.
79. Meredith EJ, Holder MJ, Chamba A, et al: The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: Probing a potential anti-tumor target for psychotropics. FASEB J 19:1187-1189, 2005.
80. Schuster C, Fernbach N, Rix U, et al: Selective serotonin reuptake inhibitors - a new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol 74:1424-1435, 2007.
81. Cortes J, Thomas D, Rios A, et al: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492-1499, 2002.
82. Galicier L, Fieschi C, Borie R, et al: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: A prospective study. 110:2846-2854, 2007.
83. Wang ES, Straus DJ, Teruya-Feldstein J, et al: Intensive chemotherapy with cyclophosphamide, doxorubicine, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/ IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98:1196-1205, 2003.
84. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab dose not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005.
85. Boue F, Gabarre J, Gisselbrecht C, et al: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 24:4123-4128, 2006.
86. Lopez T, Hagenmeister F, McLaughlin P, et al: Small noncleaved cell lymphoma in adults: Superior results for stages I-III disease. J Clin Oncol 8:615-622, 1990.
87. McMaster M, Greer J, Greco A, et al: Effective treatment of small-noncleaved- cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol 9:941-946, 1991.
88. Di Nicola M, Carlo-Stella C, Mariotti J, et al: Adult Burkitt's lymphoma: High response rate with an intensive, short-term chemotherapy program (abstract 4741). Blood 100:300b, 2002.
89. Kujawski L, Longo WL, Williams EC, et al: High-dose CHOP and midcycle methotrexate for adult Burkitt and Burkitt-like lymphomas (abstract 3083). Blood 100:779a, 2002.